Nevada · 87635

Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Nevada

Nevada Medicare Avg
$50.05
0% below national avg
National Medicare Avg
$50.08
All states combined
Billed Charge (NV)
$135.33
What providers submit
Est. Commercial (NV)
$120.12
National avg: $112.17
Est. Cash / Self-Pay (NV)
$74.75
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

1.3K
Services in NV
83
Providers
N/A
Min Payment
N/A
Max Payment

Nevada Pricing in Context

In Nevada, CPT code 87635 (Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen) carries an average Medicare payment of $50.05 — 0% below the national benchmark of $50.08. 83 providers across the state submitted claims for this procedure in 2023, performing 1.3K total services. Individual payments in NV ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Nevada is $135.33, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Nevada sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Nevada lands near $120.12, with self-pay cash prices typically around $74.75. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cost in Nevada?

The average Medicare payment for Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Nevada is $50.05, which is 0% below the national average of $50.08. Providers in NV typically bill $135.33 for this procedure.

What does Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cost with insurance in Nevada?

With commercial insurance in Nevada, Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen costs an estimated $120.12. Without insurance, the estimated cash price is $74.75. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in Nevada?

83 providers in Nevada billed Medicare for Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen in 2023, performing 1.3K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen cheaper in Nevada than the national average?

Yes — Amplifed Dna Or Rna Probe Detection Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antigen costs 0% below the national average in Nevada. The state average Medicare payment is $50.05 compared to $50.08 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial